These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 17931155

  • 1. Immunostimulatory DNA as a vaccine adjuvant.
    Higgins D, Marshall JD, Traquina P, Van Nest G, Livingston BD.
    Expert Rev Vaccines; 2007 Oct; 6(5):747-59. PubMed ID: 17931155
    [Abstract] [Full Text] [Related]

  • 2. Immune mechanisms and therapeutic potential of CpG oligodeoxynucleotides.
    Wilson HL, Dar A, Napper SK, Marianela Lopez A, Babiuk LA, Mutwiri GK.
    Int Rev Immunol; 2006 Oct; 25(3-4):183-213. PubMed ID: 16818371
    [Abstract] [Full Text] [Related]

  • 3. Presence of CpG DNA and the local cytokine milieu determine the efficacy of suppressive DNA vaccination in experimental autoimmune encephalomyelitis.
    Lobell A, Weissert R, Eltayeb S, Svanholm C, Olsson T, Wigzell H.
    J Immunol; 1999 Nov 01; 163(9):4754-62. PubMed ID: 10528174
    [Abstract] [Full Text] [Related]

  • 4. Recent advances in the development of immunostimulatory oligonucleotides.
    Uhlmann E, Vollmer J.
    Curr Opin Drug Discov Devel; 2003 Mar 01; 6(2):204-17. PubMed ID: 12669456
    [Abstract] [Full Text] [Related]

  • 5. Adjuvant properties of CpG oligonucleotides in primates.
    Verthelyi D.
    Methods Mol Med; 2006 Mar 01; 127():139-58. PubMed ID: 16988453
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. CpG motifs for optimization of DNA vaccines.
    Davis HL.
    Dev Biol (Basel); 2000 Mar 01; 104():165-9. PubMed ID: 11713816
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. TLR9 agonists as adjuvants for prophylactic and therapeutic vaccines.
    Daubenberger CA.
    Curr Opin Mol Ther; 2007 Feb 01; 9(1):45-52. PubMed ID: 17330401
    [Abstract] [Full Text] [Related]

  • 13. In vitro assay of immunostimulatory activities of plasmid vectors.
    Jiang W, Reich CF, Pisetsky DS.
    Methods Mol Med; 2006 Feb 01; 127():55-70. PubMed ID: 16988446
    [Abstract] [Full Text] [Related]

  • 14. DNA vaccines in sheep: CTLA-4 mediated targeting and CpG motifs enhance immunogenicity in a DNA prime/protein boost strategy.
    Kennedy NJ, Spithill TW, Tennent J, Wood PR, Piedrafita D.
    Vaccine; 2006 Feb 13; 24(7):970-9. PubMed ID: 16242220
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Synthetic methylated CpG ODNs are potent in vivo adjuvants when delivered in liposomal nanoparticles.
    Chikh G, de Jong SD, Sekirov L, Raney SG, Kazem M, Wilson KD, Cullis PR, Dutz JP, Tam YK.
    Int Immunol; 2009 Jul 13; 21(7):757-67. PubMed ID: 19502586
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Recent advances in immunostimulatory CpG oligonucleotides.
    Rothenfusser S, Tuma E, Wagner M, Endres S, Hartmann G.
    Curr Opin Mol Ther; 2003 Apr 13; 5(2):98-106. PubMed ID: 12772497
    [Abstract] [Full Text] [Related]

  • 19. Decreased suppression of immune stimulatory CpG motifs in plant DNA.
    Wang Y, Zhou J, Liu B.
    Immunol Lett; 2007 Dec 15; 114(2):73-80. PubMed ID: 17889375
    [Abstract] [Full Text] [Related]

  • 20. Enhancing immunogenicity by CpG DNA.
    Jiang W, Pisetsky DS.
    Curr Opin Mol Ther; 2003 Apr 15; 5(2):180-5. PubMed ID: 12772509
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.